Hypercoagulable state (thrombophilia)

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Inherited thrombophilias

• Prothrombin gene mutation (G20210A)
• Factor V Leiden mutation
• Antithrombin III deficiency
• Protein C deficiency
• Protein S deficiency
• Dysfibrinogenemia

Controversial:

• Plasminogen deficiency
• Factor XII deficiency

Acquired thrombophilias and clotting risk factors

• Surgery, foreign bodies such as venous catheters, smoking, obesity, elevated factor VIII, advanced age, male sex, trauma, sedentary state, immobilization, malignancy, myeloproliferative disorders-- polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), pregnancy, medications--e.g. Bevacizumab (Avastin), Lenalidomide (Revlimid), Thalidomide (Thalomid), Tamoxifen (Nolvadex), oral contraceptive use, heparin--in the case of heparin-induced thrombocytopenia/thrombosis (HIT), congestive heart failure, anatomic/low cardiovascular flow states--e.g. inferior vena cava (IVC) abnormalities, chronic inflammation, inflammatory bowel disease, nephrotic syndrome, paroxysmal noctural hemoglobinuria (PNH)
• Prior venous thromboembolism (VTE)
• Antiphospholipid antibody syndrome (APS)
  • Lupus anticoagulant: dilute Russell viper venom time (dRVVT), dilute activated partial thromboplastin time (dAPTT), Staclot LA (hexagonal phase phospholipids), Kaolin clotting time (KCT)
  • Anticardiolipin (aCL) antibody IgG, IgM, IgA
  • Beta 2 glycoprotein 1 (B2GP1) IgG, IgM, IgA
  • Sapporo criteria for APS